Saez-Ayala, Magali http://orcid.org/0000-0002-8726-0053
Hoffer, Laurent http://orcid.org/0000-0003-1906-7128
Abel, Sébastien
Ben Yaala, Khaoula
Sicard, Benoit
Andrieu, Guillaume P. http://orcid.org/0000-0003-0289-4952
Latiri, Mehdi
Davison, Emma K. http://orcid.org/0000-0002-9280-2742
Ciufolini, Marco A.
Brémond, Paul http://orcid.org/0000-0001-5263-3473
Rebuffet, Etienne http://orcid.org/0000-0001-5192-907X
Roche, Philippe http://orcid.org/0000-0002-5580-0588
Derviaux, Carine
Voisset, Edwige http://orcid.org/0000-0002-0943-4847
Montersino, Camille http://orcid.org/0000-0001-7024-5327
Castellano, Remy
Collette, Yves http://orcid.org/0000-0001-5359-7099
Asnafi, Vahid
Betzi, Stéphane http://orcid.org/0000-0001-5935-5058
Dubreuil, Patrice http://orcid.org/0000-0003-1155-1150
Combes, Sébastien http://orcid.org/0000-0002-8213-2407
Morelli, Xavier http://orcid.org/0000-0001-8101-7901
Article History
Received: 22 September 2022
Accepted: 11 May 2023
First Online: 29 May 2023
Competing interests
: M.S.A., L.H., S.A., K.B.Y., B.S., P.B., E.R., P.R., S.B., P.D., S.C., and X.M. are inventors of a patent entitled “Deoxycytidine kinase inhibitors” filed by the Centre National de la Recherche Scientifique on January 17, 2022 (EP 22 30 5038). The invention relates to the deoxycytidine kinase inhibitors and their uses for treating cancer. The remaining authors declare no competing interests.
: All animal experiments were performed using standard methods in agreement with the French Guidelines for animal handling and approved by the local ethics committee (CREMEAS, CEEA 35) according to the APAFiS procedure (agreement numbers APAFIS#6743 and APAFIS#19987). Patients were enrolled in the GRAALL-2003-2005 trials (registered on ExternalRef removed as follows: GRAALL-2003, #NCT00222027; GRAALL-2005, #NCT00327678). Patient samples were collected after informed consent according to the Declaration of Helsinki.